While the general markets are leaning toward positive territory following a quiet summer period, the enthusiasm for biopharma equities remains muted. One of the most closely monitored therapeutic areas is oncology. Earlier this year, public companies developing innovative medicines in that area had enjoyed strong support; however, investors now appear to be more selective in backing companies in that sector.

Year-to-date money raised in public, private and other financings of biopharma companies.

Abalos Therapeutics GmbH raised €12 million (US$13.2 million) in series A funding to advance a distinctive approach to harnessing viruses for immuno-oncology applications.

The Congressional Budget Office is estimating $345 billion could be saved in direct federal spending on Medicare Part D prescription drugs from 2023 through 2029 if H.R. 3, the Lower Drug Costs Now Act, was passed.

"With any traditional antidepression medicine, it takes three, four, six weeks before you see a response. With this class of drug, on day four, boom, there is a connection between it and lifting depression."

New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress in Barcelona.

Regulatory decisions affecting biopharma products in development, including approvals, recommendations, rejections and the granting of regulatory pathways, in September 2019.

The top 10 biopharma stock gainers and losers for the week of Oct. 14–18, 2019.

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

The number of biopharma deals and mergers and acquisitions completed are on a downward slide quarter-by-quarter, although when taken as a whole, the industry in 2019 has completed as many transactions and is hitting a higher deal value than the year before, while M&A values are up by 32%.